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The triple-negative breast cancer (TNBC) is characterized by a more aggressive nature
and poorer prognosis, nowadays none pharmaceutical approach is still available. For
this reason, the research of new active compounds and attractive targets represents
an interesting field. In this context MDA- MB-231 cell line was selected to evaluate
the antiproliferative effects of new [1,2-a]-pyrroloquinoxaline derivatives. The MTT assay
revealed that the amine forms of synthesized molecules were more active compared
to iminic ones at 72 h of incubation. The antiproliferative effect of the most promising
compounds highlighted the formation of autophagic vacuoles.
Keywords: pyrroloquinoxalines, triple-negative breast cancer, autophagy, antiproliferative activity, one-pot
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INTRODUCTION
Breast cancer (BC) is a heterogeneous and complex disease and one of the leading causes of death in
40–59 years old women. An estimated 1 million cases of BC are diagnosed annually worldwide and
of these, about 170,000 possess a triple negative (TNBC) phenotype (Plasilova et al., 2016). TNBC
is characterized by low estrogen and progesterone receptors expressions as well as low HER2/Neu
amplification. TNBC is shows a high rate of early recurrence and distant metastasis (Al-Mahmood
et al., 2018). Given the aggressive nature of TNBC an accurate diagnosis is of pivotal importance
for optimal therapy and prognosis. While ER+ and PR+ and HER2/Neu+ BC are responsive to
hormone or targeted therapy respectively, TNBC is still an orphan disease in terms of therapeutic
progress. Treatment options beyond the conventional chemotherapy include EGFR, VEGF, and
PARP inhibitors (Dawson et al., 2009). These last have shown a strong component of nitrogenous
nuclei. Studies performed on TNBC cell line have shown an antiproliferative activity for molecules
endowing a pyrroloquinoxaline nucleus, the pyrrolo[2,3-b]quinoxalines. In addition, SAR studies,
based on new pyrrolo[1,2-a]quinoxalines, demonstrated the importance of substitution in the C-4
position of the pyrrolequinoxaline nucleus and the need for a functionalization of the pyrrole ring
(Prasad et al., 2013). Therefore, other studies were performed on breast cancer cell lines expressing
the G protein-coupled estrogen receptor (GPER o GPR30) and was evaluated and attributed an
antiproliferative activity to molecules with pyrrole[1,2-a]quinoxaline structure (Aiello et al., 2017).
In the present study (Amendola, 2018), the antiproliferative activity of new molecules
with pyrrole[1,2-a]quinoxaline scaffold, on TNBC cell line MDA-MB-231 was evaluated. The
aminic/iminic form of all the new compounds were obtained by a One-Pot reaction. Results from
MTT assay, revealed that the amine forms are more active compared to iminic ones. A significant
decrease of cell viability was achieved at 72 h, highlighting the formation of autophagic vacuoles
stained by monodansylcadaverine (MDC).
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MATERIALS AND METHODS
General Synthetic Procedure
All reagents used in this synthesis, equipment, and spectroscopic
data are reported in the Supplementary Information. In
a round-bottom flask containing 5mL ethanol (96◦), p-
toluensulphonic acid (0.13 mmol) and the appropriate aldehyde
(1.26 mmol) were mixed. After 5min, 2-(1H-pyrrol-1-yl) aniline
(1.26 mmol) was added. The resulting mixture was stirred for
30min at room temperature. Then, the solvent was removed
under reduced pressure. The residue was dissolved in ethyl
acetate (50mL) and extracted with a 5% aqueous solution
of NaHCO3 (3 x 50mL). The combined organic layers were
made anhydrous with Mg2SO4, filtered and concentrated under
reduced pressure. The pure compounds were obtained after
purification with column chromatography using a mixture n-
hexane: ethyl acetate as eluent.
Cell Culture and MTT Proliferation Assay
The human epithelial breast carcinoma MDA-MB-231 cells were
purchased from the American Type Culture Collection (ATCC).
Cells were cultured in Dulbecco’s modified Eagle’s medium
SCHEME 1 | Synthetic method to obtain the pirrole[1,2-a]quinoxalines L1-10.
(DMEM) (Corning, Cellgro) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen) and maintained in a humidified
5% CO2 incubator at 37
◦C as recommended by ATCC. Cell
viability was determined by measuring the reduction of 3-(4, 5-
dimethylthiasol-2-yl)-2, 4,- diphenyltetrazolium bromide (MTT)
by mitochondrial succinate dehydrogenase. Briefly, cells were
seeded at 1 × 104 and incubated with various concentrations
of compounds L1-10 (1–20µM) alone or with DMSO (as a
vehicle) in 96-well plates for 24 and 72 h. The optical density
(OD) was calculated as the difference between the absorbance at
the reference wavelength (620 nm) and the absorbance at the test
wavelength (570 nm). Percent viability was calculated as (OD of
drug treated sample/OD of control)×100.
DAPI and MDC Staining
Changing in morphology for nuclei swelling or autophagic
vacuoles formation were assessed by 4,6-diamidino-2-
phenylindole (DAPI) or monodansylcadaverine (MDC)
staining. 1 x 105 MDA-MB-231 cells were grown on covers lip in
24-well plates and treated with L1, L5, and L6 at 20µM at 72 h.
Cells were fixed with 4% paraformaldehyde (ThermoScientific)
and imaged using by a fluorescent microscope. At least tree
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visual fields were analyzed under fluorescence microscope (Leica
FL560 fluorescence microscopy) for each sample.
Statistical Analysis
Data were expressed as mean ± standard deviation from three
independent experiments ran in triplicate. Statistical differences
were determined by one-way analysis of variance (ANOVA)
followed by Tukey’s Multiple Comparison Test. Differences were
considered statistically significant for p < 0.05 (∗), p < 0.01 (∗∗),
p < 0.001 (∗∗∗).
RESULTS
One-Pot Synthesis of Pyrrolequinoxaline
Derivatives
The synthesis of pirrolo[1,2-a]quinoxalines L1-10 (Scheme 1)
was carried out according to a very efficient one-pot reaction.
(Preetam and Nath, 2015; Aiello et al., 2017) that allows
to obtain both aminic/iminic form for some of all prepared
compound. Particularly, for L6, 8, 9 it was registered the
formation of the iminic form only. The characteristic signals of
FIGURE 1 | (A) Cell viability of L1-L10 compounds at 20 µM on MDA-MB231 at 24 h of incubation and (B) at 72 h. (C) Nuclear swelling indicated by white arrows
and stained with DAPI. (D) Autophagic activity labeling vacuoles which exhibit lysosomal activity by MDC.
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the diverse structures, used to verify which form were obtained
were the -NH (5.20–5.30 ppm) and -CH (5.10–5.20 ppm) of





To determine whether the new derivatives provide the desired
TNBC antiproliferative activity, MDA-MB-231 cell line, were
exposed to several concentration of L1-6 L8-10 for 24 or 72 h
and then cell viability was assessed by MTT assay Figures 1A,B.
Although the small number of compounds, the in vitro results
indicate the impact of the different substituents on the anti-
proliferative activity. As shown in Figure 1A, the compound
L5, that is the aminic form of L6 with an indole substituent
on C4 position, inhibited the cell proliferation at 24 h, whereas
the other compounds were ineffective, out contrary L1, bearing
a vanillic residue on C4, induced proliferation. On the other
hand, at 72 h all the synthetic compounds highlighted a decrease
of the proliferation rate, including L1 (Figure 1B). Particularly,
L1, 5 and 6, resulted in a potent cytotoxicity effect which was
able to induced nuclear swelling stained with DAPI Figure 1C
suggesting autophagic cell death. To confirm this hypothesis,
autophagic cell activity was evaluated by labeling vacuoles with
MDC dye.We appreciated, positive labeling byMCD as shown in
Figure 1D. EC50 was calculated with GraphPad Prism 5.0 using
the non-linear regression curve fit. To straight our observations
L1,5,6 were tested on MDA-MB-468 cell line, pointing out a
vitality decreasing of 36, 40, and 41% respectively.
DISCUSSION
Autophagy is a self-eating behavior initiated by cells as a
protective and pro-survival pathway against DNA damage as
well as by metabolic and therapeutic stress. When excessive
this process can lead to cell death in many type of cancers
including breast (Perri et al., 2010, 2018). To the best of our
knowledge, the in vitro results obtained in this study, it is
possible to confirm the versatility of the pyrroloquinoxaline
nucleus that once again showed interesting antiproliferative
activity assessed with MTT assay. The decrease in vitality is
due to the induction of autophagy in TNBC as it is evident by
DAPI and MDC staining. In fact, this latter staining highlighted
cells autophagic vacuoles formation after treatment with L1,
5, and 6 at 72 h. These three compounds show important
chemical differences. Firstly, L1 presents a vanillic residue on
C4 position, conversely to L5, 6, an aminic and iminic form
respectively, that bearing both an indole nucleus, and in the
case of L6 also with a bromine atom in position C7 of indole
moiety. Vanillic and indole are both privileged natural scaffolds,
able to confer important antiproliferative properties, that can
work synergistically when are linked at a pyrroloquinoxaline
nucleus, already consolidated building blocks for active and
promising anticancer agents (Aiello et al., 2017). Further, the
synthesis of new molecules is in progress aimed to verify if
the indole, on C4 position of pyrrolo[1,2-a]quinoxaline scaffold,
differently decorated with other substituents, improves the final
antiproliferative effect.
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